Hutchmed Gains as Ipsen-partnered Lymphoma Drug Undergoes Review in China
Why HUTCHMED Stock Is Moving Higher Friday
HUTCHMED (NASDAQ:HCM) stock is trading higher on Friday following the company's announcement that its New Drug Application (NDA) for Tazemetostat for the treatment of relapsed or refractory follicular
Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision
Reported Earlier, HUTCHMED Begins Phase I Clinical Trial Of Menin Inhibitor HMPL-506 For Hematological Malignancies In China
This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two p